Position in EXEL
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$568,530
+$197,318 QoQ
Shares Held
10,449
+20.7% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#412
of 754 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026AlphaCore Capital LLC holds $11,761,726 across 19 Biotechnology names. EXEL ranks #6 (4.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
40,493 | $3,169,387 | |
| 2 | IDYA |
IDEAYA Biosciences, Inc.
|
57,077 | $2,127,259 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,258 | $1,618,346 | |
| 4 | NMRA |
Neumora Therapeutics, Inc.
|
638,784 | $1,085,932 | |
| 5 | TECH |
BIO-TECHNE Corp
|
8,223 | $580,954 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
10,449 | $568,530 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
686 | $427,748 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
4,986 | $395,339 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $568,530 | 10,449 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $371,212 | 8,655 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $485,417 | 11,075 | Shares | Sole | 2026-02-05 | |
| No filing history on record for this holder in this stock. | ||||||